Bu F - Search Results

1

Repurposing drugs in autophagy for the treatment of cancer: From bench to bedside.

Bu F, Zhang J, Shuai W, Liu J, Sun Q, Ouyang L. Bu F, et al. Drug Discov Today. 2022 Jul;27(7):1815-1831. doi: 10.1016/j.drudis.2021.11.013. Epub 2021 Nov 19. Drug Discov Today. 2022. PMID: 34808390 Review.

2

Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy.

Shuai W, Wang G, Zhang Y, Bu F, Zhang S, Miller DD, Li W, Ouyang L, Wang Y. Shuai W, et al. Among authors: bu f. J Med Chem. 2021 Jun 24;64(12):7963-7990. doi: 10.1021/acs.jmedchem.1c00100. Epub 2021 Jun 8. J Med Chem. 2021. PMID: 34101463

3

Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy.

Pei J, Pan X, Wang A, Shuai W, Bu F, Tang P, Zhang S, Zhang Y, Wang G, Ouyang L. Pei J, et al. Among authors: bu f. Chem Commun (Camb). 2021 Dec 7;57(97):13194-13197. doi: 10.1039/d1cc04661f. Chem Commun (Camb). 2021. PMID: 34816823

4

Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.

Zhu Y, Shuai W, Zhao M, Pan X, Pei J, Wu Y, Bu F, Wang A, Ouyang L, Wang G. Zhu Y, et al. Among authors: bu f. J Med Chem. 2022 Mar 10;65(5):3758-3775. doi: 10.1021/acs.jmedchem.1c01947. Epub 2022 Feb 24. J Med Chem. 2022. PMID: 35200035

5

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy.

Pan X, Pei J, Wang A, Shuai W, Feng L, Bu F, Zhu Y, Zhang L, Wang G, Ouyang L. Pan X, et al. Among authors: bu f. Acta Pharm Sin B. 2022 May;12(5):2171-2192. doi: 10.1016/j.apsb.2021.12.022. Epub 2022 Jan 4. Acta Pharm Sin B. 2022. PMID: 35646548 Free PMC article. Review.

6

Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease.

Shuai W, Bu F, Zhu Y, Wu Y, Xiao H, Pan X, Zhang J, Sun Q, Wang G, Ouyang L. Shuai W, et al. Among authors: bu f. J Med Chem. 2023 Jan 26;66(2):1273-1300. doi: 10.1021/acs.jmedchem.2c01410. Epub 2023 Jan 17. J Med Chem. 2023. PMID: 36649216

7

Rational design and crystallographic analysis of novel isoform-selective TRKA inhibitors for cancer therapy.

Wang G, Wu Y, Wu C, Shuai W, Jiang T, Wang A, Bu F, Sun Q, Ouyang L. Wang G, et al. Among authors: bu f. Acta Pharm Sin B. 2023 Jan;13(1):440-443. doi: 10.1016/j.apsb.2022.10.012. Epub 2022 Oct 19. Acta Pharm Sin B. 2023. PMID: 36815052 Free PMC article. No abstract available.

8

Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer.

Pei J, Wang G, Wang A, Wu C, Pan X, Shuai W, Bu F, Zhu Y, Wang Y, Ouyang L, Li W. Pei J, et al. Among authors: bu f. J Med Chem. 2023 Apr 27;66(8):5719-5752. doi: 10.1021/acs.jmedchem.3c00027. Epub 2023 Apr 12. J Med Chem. 2023. PMID: 37042119

9

Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.

Shuai W, Xiao H, Yang P, Zhang Y, Bu F, Wu Y, Sun Q, Wang G, Ouyang L. Shuai W, et al. Among authors: bu f. J Med Chem. 2024 Apr 25;67(8):6425-6455. doi: 10.1021/acs.jmedchem.3c02392. Epub 2024 Apr 13. J Med Chem. 2024. PMID: 38613499

10

Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases.

Shuai W, Yang P, Xiao H, Zhu Y, Bu F, Wang A, Sun Q, Wang G, Ouyang L. Shuai W, et al. Among authors: bu f. Angew Chem Int Ed Engl. 2024 Dec 9;63(50):e202411037. doi: 10.1002/anie.202411037. Epub 2024 Oct 31. Angew Chem Int Ed Engl. 2024. PMID: 39276356

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

577 results

Search Page

Filters